Skip to main content

GENELUX Corp

GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001231457

In the last 90 days, GENELUX Corp insiders filed 0 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $29.5M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by GENELUX Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
7 filings
4 insiders, $194.3K in total
Insiders trading
4
Net value
−$194.3K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for GENELUX Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for GENELUX Corp
NameTitleLast reported holdingLast filingFilings, past year
Cappello JosephChief Technical Officer318,480Sep 2, 20266
Zindrick ThomasPresident and CEO1,226,427Sep 2, 20266
Yu TonyChief Scientific Officer258,688Sep 2, 20266
Smither John WDirector91,403Jul 2, 20262
Tyree James LDirector96,483Jun 18, 20261
Groen EricGeneral Counsel233,957Jun 18, 20261
Mirabelli MaryDirector102,693Jun 18, 20261
Thomas JohnDirector501,193Jun 18, 20264
Pulisic MatthewChief Financial Officer278,906Jun 18, 20261
Smalling RalphHead of Regulatory67,611Jun 4, 20264
Litten JasonChief Medical Officer–Jan 7, 20261
Ryder SeanGeneral Counsel47,621May 13, 20250
Zak Lourie S.Chief Financial Officer82,452Dec 20, 20240
Scigalla PaulChief Medical Officer–Oct 21, 20240
Szalay Aladar10% Owner599,821IndirectSep 13, 20240
Jewett CarolineHead of Quality16,174Jul 8, 20240
Samuelson DougVice President, Finance2,303Sep 12, 20230
Zhang QianAssociate VP, Research139,333May 2, 20230
Woodward GabeDirector4,186May 2, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 7, 2024 (view filing)May 299 daysLateYu TonyVP, Clinical Trial OperationsPPurchase+2.50K–––2.50K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateZindrick ThomasPresident and CEOPPurchase+200.0K––New position200.0K after
Jun 7, 2024 (view filing)May 299 daysLateZindrick ThomasPresident and CEOPPurchase+200.0K–––200.0K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateSmalling RalphHead of RegulatoryPPurchase+1.25K––+10.4%13.3K after
Jun 7, 2024 (view filing)May 299 daysLateSmalling RalphHead of RegulatoryPPurchase+1.25K–––1.25K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateRyder SeanGeneral CounselPPurchase+10.0K––+1,748.3%10.6K after
Jun 7, 2024 (view filing)May 299 daysLateRyder SeanGeneral CounselPPurchase+10.0K–––10.0K afterDerivative
Jun 7, 2024 (view filing)May 299 daysLateZak Lourie S.Chief Financial OfficerPPurchase+31.3K––New position31.3K after
Jun 7, 2024 (view filing)May 299 daysLateZak Lourie S.Chief Financial OfficerPPurchase+31.3K–––31.3K afterDerivative
May 15, 2024 (view filing)May 13-152 daysSzalay Aladar10% OwnerSSale−36.0K$3.62−$130.3K−3.1%1.14M after3 lots
May 9, 2024 (view filing)May 7-82 daysSzalay Aladar10% OwnerSSale−19.9K$3.77−$75.3K−1.7%1.18M after2 lots
May 1, 2024 (view filing)Apr 29-May 12 daysSzalay Aladar10% OwnerSSale−60.0K$3.23−$194.0K−4.8%1.20M after3 lots
Apr 24, 2024 (view filing)Apr 22-242 daysSzalay Aladar10% OwnerSSale−44.4K$3.50−$155.6K−3.4%1.26M after3 lots
Apr 18, 2024 (view filing)Apr 16-172 daysSzalay Aladar10% OwnerSSale−71.4K$3.59−$256.2K−5.2%1.30M after2 lots
Dec 18, 2023 (view filing)Dec 153 daysYu TonyVP, Clinical Trial OperationsSSale−32.5K$13.16−$428.2K−100.0%0 after2 lots
Dec 14, 2023 (view filing)Dec 131 dayTyree James LDirectorSSale−9.00K$13.21−$118.9K−72.2%3.46K after2 lots
Dec 14, 2023 (view filing)Dec 131 dayThomas JohnDirectorSSale−9.00K$13.38−$120.4K−1.9%463.5K after2 lots
Dec 8, 2023 (view filing)Dec 71 dayYu TonyVP, Clinical Trial OperationsSSale−36.8K$11.85−$436.1K−53.1%32.5K after
Nov 22, 2023 (view filing)Nov 211 dayYu TonyVP, Clinical Trial OperationsSSale−18.7K$10.26−$191.5K−21.2%69.3K after
Nov 21, 2023 (view filing)Nov 17-204 daysYu TonyVP, Clinical Trial OperationsSSale−18.1K$11.61−$210.5K−17.1%88.0K after2 lots
Oct 26, 2023 (view filing)Oct 251 daySzalay Aladar10% OwnerSSale−5.70K$19.40−$110.7K−0.4%1.37M after
Oct 25, 2023 (view filing)Oct 232 daysSzalay Aladar10% OwnerSSale−50.0K$19.97−$998.2K−3.5%1.38M after
Oct 25, 2023 (view filing)Oct 241 dayYu TonyVP, Clinical Trial OperationsSSale−5.20K$19.11−$99.4K−4.7%106.1K after
Oct 16, 2023 (view filing)Oct 16Same dayThomas JohnDirectorSSale−3.33K$20.71−$69.0K−0.7%472.5K after2 lots
Oct 11, 2023 (view filing)Oct 101 dayYu TonyVP, Clinical Trial OperationsSSale−5.20K$22.01−$114.5K−4.7%106.1K after2 lots
Oct 10, 2023 (view filing)Oct 55 daysSzalay Aladar10% OwnerSSale−14.3K$24.93−$355.3K−1.0%1.43M after2 lots
Oct 4, 2023 (view filing)Oct 31 daySzalay Aladar10% OwnerSSale−75.7K$25.49−$1.93M−5.0%1.44M after
Sep 29, 2023 (view filing)Sep 27-282 daysSzalay Aladar10% OwnerSSale−13.5K$24.41−$330.7K−0.9%1.52M after2 lots
Sep 27, 2023 (view filing)Sep 25-262 daysSzalay Aladar10% OwnerSSale−42.3K$24.38−$1.03M−2.7%1.53M after7 lots
Sep 27, 2023 (view filing)Sep 261 dayYu TonyVP, Clinical Trial OperationsSSale−5.20K$23.56−$122.5K−4.7%106.1K after3 lots
Sep 25, 2023 (view filing)Sep 21-224 daysSzalay Aladar10% OwnerSSale−16.6K$27.85−$462.0K−1.0%1.57M after4 lots
Sep 21, 2023 (view filing)Sep 201 dayYu TonyVP, Clinical Trial OperationsSSale−6.00K$27.96−$167.8K−5.4%106.1K after
Sep 21, 2023 (view filing)Sep 201 dayRyder SeanGeneral CounselSSale−10.0K$30.00−$300.0K−94.6%572 after
Sep 20, 2023 (view filing)Sep 182 daysSzalay Aladar10% OwnerSSale−30.3K$23.29−$705.6K−85.8%5.00K after2 lots
Sep 20, 2023 (view filing)Sep 191 daySzalay Aladar10% OwnerSSale−32.2K$26.45−$850.9K−100.0%0 after2 lots
Sep 18, 2023 (view filing)Sep 153 daysYu TonyVP, Clinical Trial OperationsSSale−10.4K$21.89−$227.6K−8.9%106.1K after2 lots
Sep 18, 2023 (view filing)Sep 15-183 daysThomas JohnDirectorSSale−6.67K$23.45−$156.3K−1.4%475.8K after3 lots
Sep 15, 2023 (view filing)Sep 132 daysYu TonyVP, Clinical Trial OperationsSSale−29.8K$21.14−$630.0K−21.9%106.1K after
Sep 15, 2023 (view filing)Sep 13-142 daysSzalay Aladar10% OwnerSSale−44.3K$21.80−$965.8K−55.7%35.3K after4 lots
Sep 14, 2023 (view filing)Sep 131 daySmither John WDirectorSSale−900$20.78−$18.7K−11.5%6.92K after
Sep 13, 2023 (view filing)Sep 11-122 daysSzalay Aladar10% OwnerSSale−52.6K$22.23−$1.17M−39.8%79.6K after4 lots
Sep 11, 2023 (view filing)Sep 7-84 daysSzalay Aladar10% OwnerSSale−37.3K$23.57−$878.7K−22.0%132.2K after5 lots
Aug 30, 2023 (view filing)Aug 30Same dayYu TonyVP, Clinical Trial OperationsSSale−19.8K$24.70−$489.1K−12.7%135.9K after
Aug 22, 2023 (view filing)Aug 184 daysJewett CarolineHead of QualitySSale−515$23.73−$12.2K−31.2%1.14K after
Aug 22, 2023 (view filing)Aug 184 daysSmalling RalphHead of RegulatorySSale−935$23.73−$22.2K−31.2%2.06K after
Aug 22, 2023 (view filing)Aug 184 daysSamuelson DougChief Financial OfficerSSale−1.30K$23.73−$30.8K−36.0%2.30K after
Aug 22, 2023 (view filing)Aug 184 daysRyder SeanGeneral CounselSSale−328$23.73−$7.78K−36.4%572 after
Aug 22, 2023 (view filing)Aug 184 daysCappello JosephVP, Pharmaceutical DevelopmentSSale−3.27K$23.73−$77.5K−36.3%5.74K after
Aug 22, 2023 (view filing)Aug 184 daysYu TonyVP, Clinical Trial OperationsSSale−3.27K$23.73−$77.5K−2.1%155.7K after
Aug 22, 2023 (view filing)Aug 184 daysZindrick ThomasPresident and CEOSSale−8.35K$23.73−$198.1K−36.3%14.7K after